2. Search Result
Search Result
Results for "

Ischaemia

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

2

Peptides

5

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131370B
    Intralipid 20%
    4 Publications Verification

    		 Biochemical Assay Reagents Cancer
    Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .
    Intralipid 20%
  • HY-15068
    NBQX
    Maximum Cited Publications
    20 Publications Verification

    FG9202

    		 iGluR Neurological Disease
    NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
    NBQX
  • HY-154848
    UCL-TRO-1938
    3 Publications Verification

    		 PI3K Akt Cardiovascular Disease Neurological Disease Cancer
    UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush .
    UCL-TRO-1938
  • HY-113147
    L-Palmitoylcarnitine
    2 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine
  • HY-15068A
    NBQX disodium
    Maximum Cited Publications
    20 Publications Verification

    FG9202 disodium

    		 iGluR Neurological Disease
    NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
    NBQX disodium
  • HY-113147A
    L-Palmitoylcarnitine chloride
    2 Publications Verification

    		 Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine chloride
  • HY-B1107
    Naftidrofuryl oxalate

    Nafronyl oxalate salt

    		 5-HT Receptor Cardiovascular Disease
    Naftidrofuryl oxalate (Nafronyl oxalate salt) is an orally active 5-HT2 receptor antagonist. Naftidrofuryl oxalate selectively blocks vascular and platelet 5-HT2 receptors, inhibiting Serotonin (HY-B1473A)-induced vasoconstriction, platelet aggregation, and vascular smooth muscle cell proliferation. Naftidrofuryl oxalate can be used for the research of intermittent claudication, peripheral occlusive arterial disease, and critical limb ischaemia .
    Naftidrofuryl oxalate
  • HY-113147AS
    L-Palmitoylcarnitine-d3 hydrochloride

    		Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine-d3 hydrochloride is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine-d3 hydrochloride
  • HY-152086
    DRP1i27

    		Dynamin Cardiovascular Disease
    DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .
    DRP1i27
  • HY-148327
    AK-IN-1

    		Adenosine Kinase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .
    AK-IN-1
  • HY-107571
    VULM 1457

    		Acyltransferase Cardiovascular Disease Metabolic Disease
    VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .
    VULM 1457
  • HY-152086A
    DRP1i27 dihydrochloride

    		Dynamin Cardiovascular Disease
    DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .
    DRP1i27 dihydrochloride
  • HY-157088
    C105SR

    		Caspase Apoptosis Cyclophilin Others
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
    C105SR
  • HY-113147B
    L-Palmitoylcarnitine TFA
    2 Publications Verification

    		 Endogenous Metabolite Potassium Channel Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine TFA
  • HY-103435
    Vialinin A
    2 Publications Verification

    Terrestrin A

    		 Deubiquitinase TNF Receptor E1/E2/E3 Enzyme Keap1-Nrf2 Inflammation/Immunology Cancer
    Vialinin A (Terrestrin A) is a p-terphenyl compound that can be derived from a Chinese edible mushroom. Vialinin A is an inhibitor of ubiquitin-specific peptidase 4 (USP4) and has anti-inflammatory and antioxidant properties. Vialinin A can alleviate cerebral ischaemia-reperfusion injury-induced neurological deficits and neuronal apoptosis. Vialinin A promotes activation of Keap1-Nrf2-ARE signaling pathway and increases the protein degradation of Keap1. Vialinin A possesses various pharmacological activities in cancer, Kawasaki disease, asthma, and pathological scarring. Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A can be studied in reseach for autoimmune diseases, cancer and ischaemic stroke .
    Vialinin A
  • HY-117699
    Fluanisone

    		Biochemical Assay Reagents Neurological Disease
    Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia .
    Fluanisone
  • HY-121012
    (rac)-AG-205

    		NF-κB Akt Endocrinology
    (rac)-AG-205 is a potent inhibitor of progesterone receptor membrane component 1 (Pgrmc1) that induces genes involved in sterol synthesis, including the INSIG1 protein, which forms a complex with PGRMC1. (rac)-AG-205 prevents neuronal resistance to hypoxic ischaemia by blocking NF-kB signalling and activation of the BDNF/PI3K/AKT pathway .
    (rac)-AG-205
  • HY-W392413
    Glutathione monoethyl ester

    		Drug Derivative Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis .
    Glutathione monoethyl ester
  • HY-155941
    5-Hydroxydecanoic acid

    		Potassium Channel Neurological Disease
    5-Hydroxydecanoic acid (5-HD） is a KATP channel antagonist，which has the effect of blocking the K KATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic KATP channels .
    5-Hydroxydecanoic acid
  • HY-121166
    Levobetaxolol

    (S)-Betaxolol

    		 Adrenergic Receptor Others
    Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .
    Levobetaxolol
  • HY-15068AR
    NBQX disodium (Standard)

    FG9202 disodium (Standard)

    		 iGluR Reference Standards Neurological Disease
    NBQX (disodium) (Standard) is the analytical standard of NBQX (disodium). This product is intended for research and analytical applications. NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
    NBQX disodium (Standard)
  • HY-P2696
    EP 80317

    		Transmembrane Glycoprotein Cardiovascular Disease
    EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease .
    EP 80317
  • HY-107526
    (Rac)-ALX 5407

    (Rac)-NFPS

    		 GlyT Neurological Disease
    NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC50s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .
    (Rac)-ALX 5407
  • HY-128128
    ASN04421891

    		Transmembrane Glycoprotein Cardiovascular Disease Neurological Disease Inflammation/Immunology
    ASN04421891 is a GPR17 agonist with nanomolar EC50 and high specificity. ASN04421891 promotes oligodendrocyte precursor cell maturation to mature myelinating oligodendrocytes. ASN04421891 can be used for the research of cerebral ischaemia, cardiac ischaemia, renal ischaemia, cerebral trauma, multiple sclerosis, schizophrenia, depression, alzheimer's disease, alzheimer-like dementia, parkinson's disease, huntington's chorea, amyotrophic lateral sclerosis (ALS), neuroinflammatory disorders .
    ASN04421891
  • HY-101101
    L-701252

    		iGluR Neurological Disease
    L-701252 is a potent antagonist of glycine site NMDA receptor with an IC50 of 420 nM. L-701252 provides a small degree of neuroprotection in global cerebral ischaemia .
    L-701252
  • HY-128503
    TEI-2306

    		HIV Infection Cardiovascular Disease
    TEI-2306 is a precursor of glutathione biosynthesis. TEI-2306 possesses a unique anti-HIV-1 activity in both chronically and acutely infected cells, and even for free viruses. TEI-2306 can be used for the study of myocardial ischaemia .
    TEI-2306
  • HY-106754
    FLM-5011

    		Lipoxygenase Cardiovascular Disease Inflammation/Immunology
    FLM-5011 is a lipoxygenase inhibitor. FLM-5011 can diminish myocardial ischaemia injury and shows anti-inflammatory effect. FLM-5011 can be used for the researches of inflammation and cardiovascular disease, such as myocarditis .
    FLM-5011
  • HY-113147AR
    L-Palmitoylcarnitine chloride (Standard)

    		Reference Standards Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine (chloride) (Standard) is the analytical standard of L-Palmitoylcarnitine (chloride). This product is intended for research and analytical applications. L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].
    L-Palmitoylcarnitine chloride (Standard)
  • HY-131041
    Ned-K

    		Calcium Channel Cardiovascular Disease
    Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca 2+ oscillations in cardiomyocytes .
    Ned-K
  • HY-108515
    (+)-Igmesine hydrochloride

    JO1784

    		 Sigma Receptor NO Synthase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    (+)-Igmesine hydrochloride (JO1784) is an orally active and selective σ1 receptor ligand with an IC50 of 39 nM. (+)-Igmesine hydrochloride binds σ1 receptors to activate G-proteins and modulate Ca 2+ uptake. (+)-Igmesine (hydrochloride) attenuates ischaemia-induced nitric oxide synthase activity and hyperactivity. (+)-Igmesine hydrochloride can be used for the research of duodenal ulcers, gastric ulcers, and cerebral ischaemia .
    (+)-Igmesine hydrochloride
  • HY-N6634
    Araloside C

    		Autophagy HSP Others
    Araloside C is a natural saponin that is mainly isolated from Aralia elata. Araloside C exerts extensive anti-inflammatory properties. Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury .
    Araloside C
  • HY-106039
    LY 215490

    		iGluR Neurological Disease
    LY 215490 is a selective, competitive AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC50 values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .
    LY 215490
  • HY-15068R
    NBQX (Standard)

    FG9202 (Standard)

    		 iGluR Reference Standards Neurological Disease
    NBQX (Standard) is the analytical standard of NBQX. This product is intended for research and analytical applications. NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
    NBQX (Standard)
  • HY-117699R
    Fluanisone (Standard)

    		Biochemical Assay Reagents Reference Standards Neurological Disease
    Fluanisone (Standard) is the analytical standard of Fluanisone. This product is intended for research and analytical applications. Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia .
    Fluanisone (Standard)
  • HY-133173
    Niravoline

    RU51599

    		 Vasopressin Receptor Opioid Receptor Neurological Disease
    Niravoline (RU51599) is an arginine vasopressin (AVP) release inhibitor and a selective kappa opioid receptor agonist. Niravoline has a pure water diuresis effect without associated electrolyte excretion. Niravoline can reduce brain oedema following transient forebrain ischaemia in rats .
    Niravoline
  • HY-113147S1
    L-Palmitoylcarnitine-d9

    		Isotope-Labeled Compounds Potassium Channel Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    L-Palmitoylcarnitine-d9 is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine-d9
  • HY-152013S
    L-Palmitoylcarnitine-d3-1 hydrochloride

    		Isotope-Labeled Compounds Endogenous Metabolite Potassium Channel Cardiovascular Disease
    L-Palmitoylcarnitine-d3-1 (hydrochloride) is deuterium labeled L-Palmitoylcarnitine (chloride). L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .
    L-Palmitoylcarnitine-d3-1 hydrochloride
  • HY-101337
    Imiloxan

    RS 21361 free base

    		 Adrenergic Receptor Inflammation/Immunology
    Imiloxan (RS 21361) is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan has the potential for acute kidney injury research .
    Imiloxan
  • HY-116244
    Ro 48-8587

    		iGluR Cardiovascular Disease Neurological Disease
    Ro 48-8587 is a selective AMPA receptor antagonist with an IC50 of 8 nM. Ro 48-8587 functionally inhibits AMPA receptor activity, blocks AMPA-induced depolarization of rat cortical wedges. Ro 48-8587 can be used for the research of ischaemia and seizures .
    Ro 48-8587
  • HY-105261
    Idrapril

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Idrapril is an ACE inhibitor. Idrapril can be studied in research on acute myocardial ischaemia and reperfusion .
    Idrapril
  • HY-U00134A
    Bencyclane fumarate

    		Calcium Channel Cardiovascular Disease
    Bencyclane (fumarate) is a vasodilating calcium channel blocker. Bencyclane (fumarate) can attenuate mucosal damage in intestinal ischaemia reperfusion injury rat model. Bencyclane (fumarate) can be studied in research on peripheral arterial occlusice diseases .
    Bencyclane fumarate
  • HY-P2696A
    EP 80317 acetate

    		Transmembrane Glycoprotein Cardiovascular Disease
    EP 80317 acetate is a selective CD36 ligand. EP 80317 acetate protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 acetate can be used for the study of cardiovascular disease .
    EP 80317 acetate
  • HY-107571R
    VULM 1457 (Standard)

    		Reference Standards Acyltransferase Cardiovascular Disease Metabolic Disease
    VULM 1457 (Standard) is the analytical standard of VULM 1457 (HY-107571). This product is intended for research and analytical applications. VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .
    VULM 1457 (Standard)
  • HY-123255
    BSc2118

    		Proteasome MMP Apoptosis Autophagy Cardiovascular Disease Neurological Disease Cancer
    BSc2118 is a 20S proteasome inhibitor with an IC50 of approximately 50 nM. BSc2118 induces G2/M phase cell cycle arrest and apoptosis in myeloma cells, inhibits cytoprotective autophagy, and suppresses tumor angiogenesis. BSc2118 reduces MMP9 activity, promotes angioneurogenesis, and alleviates recombinant tissue-type plasminogen activator-induced cerebral toxicity. BSc2118 is applicable to studies related to cerebral ischemia and multiple myeloma .
    BSc2118

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: